Business
Investor Meet Company presentation
Investor Meet Company presentation.
About this update from Ixico Plc
[{"type":"text","content":"\n\n16 May 2023\nIXICO plc\n(\"IXICO\" or the \"Company\")\n \nHalf-year results investor presentation via Investor Meet Company.\nIXICO PLC is pleased to announce that Giulio Cerroni (CEO), Grant Nash (CFO) and Robin Wolz (CSO) will provide a live presentation relating to the half-year results of the Company via the Investor Meet Company platform on 23rd May 2023 at 4:30pm BST. The presentation is open to all existing and potential shareholders.\nQuestions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.\nInvestors can sign up to Investor Meet Company for free and add to meet IXICO PLC via: https://www.investormeetcompany.com/ixico-plc/register-investor.\n\nInvestors who already follow IXICO PLC on the Investor Meet Company platform will automatically be invited.\n \nFor further information please contact:\n \n\n\n\nIXICO plc\n\n\n+44 (0)20 3763 7499\n\n\n\n\nGiulio Cerroni, Chief Executive Officer\nGrant Nash, Chief Financial Officer\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n\nCenkos Securities PLC (Nominated adviser and sole broker)\n\n\n+44 (0)20 7397 8900\n\n\n\n\nGiles Balleny / Max Gould (Corporate Finance)\n\n\n\n\n\n\n\nMichael F Johnson / Tamar Cranford-Smith (Sales)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAbout IXICO | Advanced Analytics | Intelligent Insights.\nIXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis. \n \nIXICO has developed and deployed breakthrough machine learning Ai data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.\...